Aakha Biologics

Aakha Biologics is a private, pre-clinical-stage biotech focused on revolutionizing immunotherapies for solid tumors through a novel platform for multi-specific antibodies. The company integrates multiple synergistic mechanisms into single molecules to efficiently target tumors and activate immune cells like T cells and NK cells. Backed by experienced leadership, a strong scientific advisory board, and strategic partnerships, Aakha has secured non-dilutive funding and entered into a licensing agreement to advance its pipeline. Its approach aims to address the significant unmet need in oncology by creating powerful, elegant therapeutic solutions for patients with limited options.

Modular, multi-pronged platform for designing first-in-class, multi-specific antibodies that block disease-driver pathways and engage optimal immune activation (NK cells & T cells) for solid tumors.

Aakha operates in the highly competitive field of multi-specific antibody therapeutics for oncology, competing with numerous established biopharma companies (e.g., Genentech/Roche, Amgen) and agile biotechs (e.g., Compass Therapeutics, IGM Biosciences). Differentiation will require demonstrating superior efficacy, safety, or novel target combinations in solid tumors, an area where current immunotherapies often fail.